Industry Focus

We love covering IPOs, but we can't bring ourselves to buy a stock that's only been publicly traded for a few months. We explain why on the final episode of "never will I ever week."

 We all make investing mistakes, but buying a commodity producer lacking a cost advantage shouldn’t be one of them.

Only 10% of drugs make it across the FDA finish line from phase 1 clinical trials, making acquiring pre-clinical biotech stocks the riskiest game in town.

We continue with our theme for this week, as Asit Sharma explains the major hurdles day traders and speculators face in their pursuit of easy profits.

In this episode of Industry Focus: Financials, we dig into things we'd never do -- or, at least, that we try to avoid. This includes investing advice, as well as pointers about life more generally.

Looking for a beach read or a podcast to pass the time on the family trip? We run through some of our favorite tech books and shows so you can still get your fix during the slow months of summer.

Thanks to Slack for supporting Motley Fool. Learn more at slack.com.

Is being late better than never arriving for America's biggest oil major?

After Walgreens' abandoned plans to buy it lock-stock-and-barrel, Rite Aid shares are crashing. Does this give Amazon.com the moment it's been waiting for to disrupt the prescription drug market?

Thanks to Slack for supporting Motley Fool. Learn more at slack.com.

There's no one, right answer, but getting a job while in school can help teach a lot of important things. Tune in to find out what Motley Fool contributors Dan Kline and Gaby Lapera think you ought to know.

In the past month, Pandora has sold off Ticketfly, announced a large investment stake from Sirius, and had its CEO step down. What should investors make of the shake-up? Plus we check in on Apple Music and Tesla's puzzling streaming music ambitions.